ERIS Lifesciences Ltd

- Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16). - CapEx for FY26 Q3 was about INR 80 crore, with nine-month CapEx around INR 200 crore, targeting Insulin, GLP-1, and Injectable projects (Page 5). - The 3-year CapEx guidance remains around INR 200-250 crore per annum, totaling approximately INR 750 crore for FY26-FY28 (Pages 5 and 6). - Investment front-loaded to capitalize on strategic opportunities in Injectable Insulin and GLP segments (Page 6). - New manufacturing Unit 3 at Swiss facility to be commissioned in FY28, significantly expanding capacity for CDMO business (Page 15). - Strategic expansion planned with strong growth visibility in international business, including CDMO clients in regulated markets expected to contribute INR 550-600 crore in FY27 (Page 16).

- Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. - DBF segment targets a 37% operating margin this year and 39%+ EBITDA margin next year. - Significant market share gains in the RHI insulin cartridge segment: from 8% at acquisition to 25-26% by Dec-Jan, with further growth expected in the RHI plus Glargine segment over the next 3 years. - International business delivered 45% revenue growth in Q3, with strong visibility for FY27 revenue between INR 550-600 crores. - CDMO revenue expected to grow, with INR 125-160 crore anticipated next year and full commercialization of a INR 1,000 crore order book over three years. - Launch of GLP-1 products (Semaglutide) expected to drive growth, with initial margin pressure but overall positive top-line impact. - Insulin production ramp-up from Bhopal expected to enhance margins and volumes. - Overall, FY27 and beyond are seen as breakout years, especially driven by international markets and new product launches.

- Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin. - Consolidated Q3 revenue grew 11% YoY to INR 807 crore with a consolidated margin expansion of 80 bps to 36% YTD. - Profit After Tax (PAT) growth from operations was about 39% in Q3. - International business is expected to reach INR 550-600 crore in revenue in FY27, marking a breakout year. - The CDMO revenue is expected to be INR 125-160 crore next year, with full commercialization of the INR 1,000 crore order book spread over three years. - FY26 EBITDA margin for DBF expected above 39%. - Operating costs from manufacturing initiatives (~INR 60-90 crore annually) likely to break even next year. - Gross margin pressure from initial GLP-1 launch expected but to be offset by DBF scale and upcoming insulin production. - EPS growth: Q3 EPS INR 9, 9M EPS INR 28, with nearly 40% PAT growth YoY.

- The current CDMO order book stands at an annualized size of INR 1,000 crore as of Q3FY26. - This INR 1,000 crore order book is additional to the existing base business, primarily from the Swiss facility. - The full commercialization and execution of this INR 1,000 crore order book is expected to take about three years. - For the next year (FY27), the company expects CDMO revenues of INR 125-160 crore. - The company has strong visibility of FY27 as a breakout year for international revenues, targeting INR 550-600 crore. - Capacity-wise, Swiss operates two facilities currently, sufficient for FY27; a third larger facility is expected by FY28. - The company may explore new CMO opportunities such as Semaglutide generics depending on approval timelines.

- No specific mention of new fundraising through debt or equity in the current quarter. - The company disclosed that CapEx guidance for the next 3 years remains unchanged at around INR 750 crore. - They are focused on managing and reducing net debt to reach a target net debt to EBITDA ratio of 1.5x by the end of the calendar year. - Debt repayment schedules remain consistent with the previous quarter; no changes reported. - Capital investments continue primarily in Injectables, Insulin, MABs, and GLP-1 projects aligned with guidance. - No explicit plans for fresh equity financing were discussed during the call.